今年作为专项接续推进的关键节点，相关工作已有序展开。 除了针对未满足临床需求，国家科技重大专项的"四个转变"也是针对当前新药研发中的短板弱项。 曹雪涛举例说，在国家战略科技力量协同方面，尽管我国已布局3家生物医药领域国家实验室，建设了 一批全国重点实验室、国家临床医学研究中心，培育了高水平研究型大学与医药创新领军企业，但仍存 在诸多问题：新型举国体制优势未充分彰显，各创新主体积极性调动不足，统筹国内优质创新资源开展 联合攻关的体系不健全，国家实验室目标任务凝练机制未完全形成，新药研发任务分散，难以形成合力 突破关键核心技术。 面向2035年，我国将从支持包括仿制药在内的新药研发向重点支持原创新药研发转变，关注重大基础研 究，聚焦"两大三特"需求，支持新药创制。 10日，国家卫健委主管期刊"中国卫生杂志"微信公号发布了中国工程院院士、创新药物研发国家科技重 大专项（下称"专项"）技术总师曹雪涛的最新演讲文章。曹雪涛表示，近年来，国家科技重大专项推进 我国新药研发逐步实现了从跟踪仿制到自主创新的跨越。针对新形势与新挑战，专项明确了新阶段"守 正创新、跨越发展"的定位，提出"四个转变"战略，推动创新药物研发从规模导 ...

Core Viewpoint - Shenzhen Chipscreen Biosciences Co., Ltd. is preparing for a specific issuance of A-shares in 2024, with Guotou Securities acting as the sponsor, ensuring compliance with relevant laws and regulations [1][2]. Group 1: Issuance Details - Guotou Securities has been appointed as the sponsor for the issuance of A-shares for Shenzhen Chipscreen in 2024, with representatives Hu Jiabin and Song Qian responsible for the due diligence and ongoing supervision [2][3]. - The issuance will involve a maximum of 58,125,305 shares, not exceeding 30% of the total share capital prior to the issuance [23][24]. Group 2: Company Overview - Shenzhen Chipscreen was established on March 21, 2001, with a registered capital of 408.54 million yuan and is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board [5]. - The company focuses on drug technology development, new drug research, and related services, with a commitment to innovation in the biopharmaceutical sector [5]. Group 3: Financial Performance - As of March 31, 2025, the total assets of the company amounted to 331,170.31 million yuan, with total liabilities of 174,984.07 million yuan [8]. - The company reported a total revenue of 16,226.37 million yuan for the first quarter of 2025, with a net loss attributable to shareholders of 1,915.47 million yuan [8]. Group 4: Shareholder Structure - As of March 31, 2025, the top ten shareholders collectively hold 41.48% of the company's shares, with significant stakes held by various investment partnerships [5][11]. - The actual controller, Xianping Lu, holds 5.45% of the shares directly and controls a total of 22.00% through various partnerships [11][12]. Group 5: Future Plans and Use of Proceeds - The funds raised from the issuance will be allocated to innovative drug research and development projects, including the establishment of a new drug manufacturing base [23][24]. - The company has not distributed profits from 2022 to 2024, focusing on reinvestment for growth and development [6].